Nektar Management to Present at Upcoming Investor Conferences

Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [2] - The lead product candidate is rezpegaldesleukin (REZPEG, or NKTR-358), a first-in-class regulatory T cell stimulator currently in two Phase 2b clinical trials for atopic dermatitis and alopecia areata [2] - The pipeline includes a preclinical candidate NKTR-0165, a bivalent tumor necrosis factor receptor type II agonist antibody, and NKTR-255, an investigational IL-15 receptor agonist aimed at enhancing the immune system's ability to combat cancer [2] Upcoming Events - Nektar Therapeutics management will present at the Jefferies Healthcare Conference in New York City on June 6, 2024, at 3:30 p.m. Eastern Time [1] - The company will also present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 10, 2024, at 2:00 p.m. Eastern Time [1] - Presentations will be accessible via webcast and available for replay until July 6, 2024, and July 10, 2024, respectively [1]